Underlying health conditions, such as hypothyroidism or PCOS, may slow your progress and are worth discussing with a licensed healthcare provider
Studies have shown that people have regained weight within a year of discontinuing semaglutide injections
However, it takes 4-8 weeks for the drug to reach a steady level in your body
Building on these research findings, Eli Lilly developed a dual agonist targeting GLP-1R/GIPR, called tirzepatide, which was approved by the FDA in 2022 and showed promising therapeutic effects for T2D and obesity
We also assess the potential mechanisms that contribute to the reduction in major adverse cardiovascular events in individuals treated with GLP1R agonists and highlight the emerging cardiovascular biology of novel GLP1-based multi-agonists currently in development
Glucose metabolism and cardiac hypertrophy